NCT01393730View on ClinicalTrials.gov

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

March 15, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone acetate

DRUG

Dutasteride

DRUG

Prednisone

Trial Locations (4)

98109

Seattle Cancer Care Alliance, Seattle

98195

University of Washington Medical Center, Seattle

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Mary-Ellen Taplin, MD

OTHER

NCT01393730 - Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter